John Sundy
Directeur/Membre du Conseil chez SANOFI
Postes actifs de John Sundy
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SANOFI | Directeur/Membre du Conseil | 30/04/2024 | - |
| Independent Dir/Board Member | 30/04/2024 | - | |
Neutrolis, Inc.
 Neutrolis, Inc. Pharmaceuticals: MajorHealth Technology Neutrolis, Inc. is a biotechnology company located in North Cambridge, MA. The company develops first-in-class therapies that target neutrophils and their pathogenic products, including nets. Neutrolis proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form nets. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis, and other net-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company was founded by Abdul Hakkim and Toby Fox. Toby Fox has been the CEO since incorporation. | Directeur/Membre du Conseil | - | - |
Historique de carrière de John Sundy
Anciens postes connus de John Sundy
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2014 | 01/04/2020 |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01/01/2006 | 01/01/2014 |
| Duke-NUS Graduate Medical School Singapore | Corporate Officer/Principal | 01/01/2006 | 01/01/2014 |
| PANDION THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/05/2020 | - |
Formation de John Sundy
| Bucknell University | Undergraduate Degree |
| Hahnemann University | Doctorate Degree |
| Drexel University College of Medicine | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 8 |
| France | 2 |
| Singapour | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Doctorate Degree | 2 |
| Director/Board Member | 2 |
Sectorielle
| Consumer Services | 6 |
| Health Technology | 5 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| SANOFI | Health Technology |
| Entreprise privées | 2 |
|---|---|
Pandion Therapeutics, Inc.
 Pandion Therapeutics, Inc. BiotechnologyHealth Technology Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded by Dr. Joanne Viney on September 19, 2016 and is headquartered in Watertown, MA. | Health Technology |
Neutrolis, Inc.
Neutrolis, Inc. Pharmaceuticals: MajorHealth Technology Neutrolis, Inc. is a biotechnology company located in North Cambridge, MA. The company develops first-in-class therapies that target neutrophils and their pathogenic products, including nets. Neutrolis proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form nets. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis, and other net-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company was founded by Abdul Hakkim and Toby Fox. Toby Fox has been the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- John Sundy
- Expérience